Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 6/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9903518 | 0.89 | PTK2 (0.56) | PTK2NPC1RAB9AGRM5DPP4 | |
| SCHEMBL9903802 | 0.89 | GRM5 (0.49) | PTK2GRM5DPP4 | |
| SCHEMBL9903792 | 0.85 | PTK2 (0.50) | PTK2NPC1RAB9ATP53GRM5 | |
| SCHEMBL9903632 | 0.75 | PTK2 (0.55) | PTK2NPC1RAB9AMAPTGRM5 | |
| SCHEMBL16151536 | 0.71 | HPGD (0.65) | GRM5HPGD | |
| SCHEMBL9903310 | 0.70 | GRM5 (0.40) | NPC1RAB9ATP53MAPTHTT | |
| SCHEMBL1657950 | 0.69 | GRM5 (0.78) | NPC1RAB9ATP53MAPTHTT | |
| SCHEMBL12731041 | 0.68 | GRM5 (0.76) | NPC1RAB9ATP53MAPTHTT | |
| SCHEMBL29944135 | 0.67 | HRH3 (0.54) | PTK2NPC1RAB9ATP53MAPT | |
| SCHEMBL9903655 | 0.67 | EGLN1 (0.40) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-07-12 | — | — | US | claimed |
| EP-2462142-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-06-13 | — | — | EP | claimed |
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-07-12 | — | — | US | disclosed |
| EP-2462142-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | GRM5, GRIK5, GRM1 | PTK2 3720/4885NPC1 1327/4885RAB9A 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.